Back to Journals » International Journal of Nanomedicine » Volume 14

Gold-quercetin nanoparticles prevent metabolic endotoxemia-induced kidney injury by regulating TLR4/NF-κB signaling and Nrf2 pathway in high fat diet fed mice [Retraction]

Authors Xu MX, Wang M, Yang WW

Received 15 April 2019

Accepted for publication 15 April 2019

Published 26 April 2019 Volume 2019:14 Pages 2961—2962


Xu M-X, Wang M, Yang W-W. Gold-quercetin nanoparticles prevent metabolic endotoxemia-induced kidney injury by regulating TLR4/NF-κB signaling and Nrf2 pathway in high fat diet fed mice. International Journal of Nanomedicine. 2017:12;327–345.

At the request of the author, the Editor-in-Chief and Publisher of the International Journal of Nanomedicine wish to retract the published article.

Following a review of their data the authors observed some of the western blot bands for Figures 6, 10, 11 and 12 had been unintentionally duplicated. The specific duplications are:
● Western blot bands for Figure 6 SOD2 have been duplicated in the western blot bands for Figure 12 Keap1
● Western blot bands for Figure 10 NF-κB have been duplicated in the western blot bands for Figure 11 GAPDH

It was determined by the authors the statistical differences indicated between the bands were no longer valid and the conclusions of the article were no longer supported.

Our decision-making was informed by our policy on publishing ethics and integrity and COPE’s retraction guidelines. The authors wish to apologize for this error.

This retraction relates to this paper

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.